acetylcarnitine has been researched along with Pain in 24 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thioctic acid 600 mg/day appears to be at least as effective as ALC in the treatment of sciatic pain caused by a herniated disc and may be associated with an improvement in symptom scores and reduced need for analgesia." | 9.13 | Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. ( Loiero, M; Memeo, A, 2008) |
| "Prophylactic treatment with acetyl-L-carnitine (ALCAR) prevents the neuropathic pain syndrome that is evoked by the chemotherapeutic agent, paclitaxel." | 7.74 | Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. ( Bennett, GJ; Flatters, SJ; Jin, HW; Mulhern, HL; Xiao, WH, 2008) |
| "This study examines the potential efficacy of acetyl-L-carnitine (ALC) to prevent and treat paclitaxel-induced pain." | 7.73 | Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. ( Bennett, GJ; Flatters, SJ; Xiao, WH, 2006) |
| "Although sciatic pain is typically self-limiting, pharmacological analgesic therapy forms the mainstay of treatment." | 6.73 | Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. ( Loiero, M; Memeo, A, 2008) |
| "Sciatica is a painful condition characterized by radiating leg pain that most commonly originates from a herniated disc in the lumbar or sacral spine." | 6.73 | Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. ( Loiero, M; Memeo, A, 2008) |
| " Evidence from animal models of chemotherapy-induced painful peripheral neuropathy produced by the taxane agent, paclitaxel, and the platinum-complex agent, oxaliplatin, indicate that they produce neuropathy via a common mechanism-a toxic effect on the mitochondria in primary afferent sensory neurons." | 5.38 | Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. ( Bennett, GJ; Xiao, WH; Zheng, H, 2012) |
| "Thioctic acid 600 mg/day appears to be at least as effective as ALC in the treatment of sciatic pain caused by a herniated disc and may be associated with an improvement in symptom scores and reduced need for analgesia." | 5.13 | Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. ( Loiero, M; Memeo, A, 2008) |
| "Prophylactic treatment with acetyl-L-carnitine (ALCAR) prevents the neuropathic pain syndrome that is evoked by the chemotherapeutic agent, paclitaxel." | 3.74 | Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. ( Bennett, GJ; Flatters, SJ; Jin, HW; Mulhern, HL; Xiao, WH, 2008) |
| "This study examines the potential efficacy of acetyl-L-carnitine (ALC) to prevent and treat paclitaxel-induced pain." | 3.73 | Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. ( Bennett, GJ; Flatters, SJ; Xiao, WH, 2006) |
| "Although sciatic pain is typically self-limiting, pharmacological analgesic therapy forms the mainstay of treatment." | 2.73 | Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. ( Loiero, M; Memeo, A, 2008) |
| "Sciatica is a painful condition characterized by radiating leg pain that most commonly originates from a herniated disc in the lumbar or sacral spine." | 2.73 | Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. ( Loiero, M; Memeo, A, 2008) |
| "Treatment of peripheral neuropathies is targeted to its symptomatic and aetiological features." | 2.44 | Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies. ( Capiluppi, E; Mailland, E; Mariani, C; Nascimbene, C; Osio, M; Vanotti, A, 2007) |
| "Peripheral neuropathies are extremely heterogeneous nosological entities." | 2.44 | Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies. ( Capiluppi, E; Mailland, E; Mariani, C; Nascimbene, C; Osio, M; Vanotti, A, 2007) |
| "Pancreatitis was induced with 6 hly intraperitoneal (i." | 1.62 | Effect of acetyl-L-carnitine on hypersensitivity in acute recurrent caerulein-induced pancreatitis and microglial activation along the brain's pain circuitry. ( High, AE; McIlwrath, SL; Saito, H; Starr, ME; Westlund, KN, 2021) |
| "Pain was measured in animals submitted to MIA model by paw pressure and compression behavioral tests in the presence or absence of ALC." | 1.40 | Prophylactic role of acetyl-l-carnitine on knee lesions and associated pain in a rat model of osteoarthritis. ( Aglianò, M; Bianchi, E; Di Cesare Mannelli, L; Ghelardini, C; Lorenzoni, P; Menicacci, C, 2014) |
| " Evidence from animal models of chemotherapy-induced painful peripheral neuropathy produced by the taxane agent, paclitaxel, and the platinum-complex agent, oxaliplatin, indicate that they produce neuropathy via a common mechanism-a toxic effect on the mitochondria in primary afferent sensory neurons." | 1.38 | Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. ( Bennett, GJ; Xiao, WH; Zheng, H, 2012) |
| "ALCAR completely prevented mechanical hyperalgesia and provoked in the nerve a c-Jun increment only." | 1.36 | The neuropathy-protective agent acetyl-L-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain. ( Bartolini, A; Di Cesare Mannelli, L; Ghelardini, C; Pacini, A; Toscano, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 8 (33.33) | 24.3611 |
| 2020's | 5 (20.83) | 2.80 |
| Authors | Studies |
|---|---|
| D'Orio, M | 1 |
| De Vitis, R | 1 |
| Taccardo, G | 1 |
| Rocchi, L | 1 |
| Ferrari, F | 1 |
| Perna, A | 1 |
| Passiatore, M | 1 |
| Salaffi, F | 1 |
| Farah, S | 1 |
| Sarzi-Puttini, P | 1 |
| Di Carlo, M | 1 |
| Lowry, E | 1 |
| Marley, J | 1 |
| McVeigh, JG | 1 |
| McSorley, E | 1 |
| Allsopp, P | 1 |
| Kerr, D | 1 |
| Ardizzone, A | 1 |
| Fusco, R | 1 |
| Casili, G | 1 |
| Lanza, M | 1 |
| Impellizzeri, D | 1 |
| Esposito, E | 1 |
| Cuzzocrea, S | 1 |
| McIlwrath, SL | 1 |
| Starr, ME | 1 |
| High, AE | 1 |
| Saito, H | 1 |
| Westlund, KN | 1 |
| Sergi, G | 1 |
| Pizzato, S | 1 |
| Piovesan, F | 1 |
| Trevisan, C | 1 |
| Veronese, N | 1 |
| Manzato, E | 1 |
| Cruccu, G | 1 |
| Di Stefano, G | 1 |
| Fattapposta, F | 1 |
| Jann, S | 1 |
| Padua, L | 1 |
| Schenone, A | 1 |
| Truini, A | 1 |
| Bianchi, E | 1 |
| Di Cesare Mannelli, L | 3 |
| Menicacci, C | 1 |
| Lorenzoni, P | 1 |
| Aglianò, M | 1 |
| Ghelardini, C | 3 |
| Traina, G | 1 |
| Memeo, A | 1 |
| Loiero, M | 1 |
| Toscano, A | 1 |
| Pacini, A | 1 |
| Bartolini, A | 2 |
| Chiechio, S | 3 |
| Copani, A | 3 |
| Zammataro, M | 1 |
| Battaglia, G | 1 |
| Gereau, RW | 2 |
| Nicoletti, F | 3 |
| Vivoli, E | 1 |
| Salvicchi, A | 1 |
| Koverech, A | 1 |
| Nicolai, R | 2 |
| Benatti, P | 1 |
| Zheng, H | 1 |
| Xiao, WH | 3 |
| Bennett, GJ | 3 |
| Melchiorri, D | 1 |
| Canudas, AM | 1 |
| Storto, M | 1 |
| Calvani, M | 2 |
| Sima, AA | 1 |
| Mehra, M | 1 |
| Amato, A | 1 |
| Flatters, SJ | 2 |
| Osio, M | 3 |
| Muscia, F | 1 |
| Zampini, L | 1 |
| Nascimbene, C | 2 |
| Mailland, E | 2 |
| Cargnel, A | 1 |
| Mariani, C | 2 |
| Youle, M | 1 |
| Vanotti, A | 1 |
| Capiluppi, E | 1 |
| Jin, HW | 1 |
| Mulhern, HL | 1 |
| Onofrj, M | 1 |
| Fulgente, T | 1 |
| Melchionda, D | 1 |
| Marchionni, A | 1 |
| Tomasello, F | 1 |
| Salpietro, FM | 1 |
| Alafaci, C | 1 |
| De Sanctis, E | 1 |
| Pennisi, G | 1 |
| Bella, R | 1 |
| Scarpini, E | 1 |
| Sacilotto, G | 1 |
| Baron, P | 1 |
| Cusini, M | 1 |
| Scarlato, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Microbiome Correlates of Dietary Interventions in Patients With Fibromyalgia and Their Association With Symptom Modification[NCT05329571] | 50 participants (Anticipated) | Interventional | 2021-03-12 | Active, not recruiting | |||
| Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome; a Randomized Control Trial.[NCT02141035] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| An Open-Label, Dose-Escalation Pilot Study of Acetyl-L-Carnitine for the Treatment of Dideoxynucleoside-Associated Distal Symmetric Peripheral Neuropathy[NCT00050271] | 27 participants (Actual) | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for acetylcarnitine and Pain
| Article | Year |
|---|---|
Dietary Interventions in the Management of Fibromyalgia: A Systematic Review and Best-Evidence Synthesis.
Topics: Acetylcarnitine; Ascorbic Acid; Chlorella; Diet, Vegan; Dietary Supplements; Fermented Foods; Fibrom | 2020 |
Effects of acetyl-L-carnitine in diabetic neuropathy and other geriatric disorders.
Topics: Acetylcarnitine; Aged; Alzheimer Disease; Analgesics; Diabetic Neuropathies; Humans; Mitochondria; P | 2018 |
The neurobiology of acetyl-L-carnitine.
Topics: Acetylcarnitine; Aging; Animals; Apoptosis; Brain; Dietary Supplements; Energy Metabolism; Epigenesi | 2016 |
Metabotropic receptors as targets for drugs of potential use in the treatment of neuropathic pain.
Topics: Acetylcarnitine; Analgesics; Animals; Humans; Nootropic Agents; Pain; Peripheral Nervous System Dise | 2004 |
Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies.
Topics: Acetylcarnitine; Analgesics, Opioid; Animals; Anticonvulsants; Antidepressive Agents; Antineoplastic | 2007 |
Acetyl-L-carnitine in neuropathic pain: experimental data.
Topics: Acetylcarnitine; Analgesia; Animals; Humans; Nootropic Agents; Pain; Peripheral Nervous System Disea | 2007 |
8 trials available for acetylcarnitine and Pain
| Article | Year |
|---|---|
Clinical usefulness of nutraceutics with acetyl-L-carnitine, α-lipoic acid, phosphatidylserine, curcumin, C, E and B-group vitamins in patients awaiting for carpal tunnel release during COVID-19 pandemic: a randomized controlled open label prospective stu
Topics: Acetylcarnitine; Carpal Tunnel Syndrome; COVID-19; Curcumin; Humans; Pain; Pandemics; Phosphatidylse | 2023 |
Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study.
Topics: Acetylcarnitine; Analgesics; Duloxetine Hydrochloride; Fibromyalgia; Humans; Pain; Pregabalin; Treat | 2023 |
Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study.
Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Analgesics; Antioxidants; Double-Blind Method; Elec | 2008 |
Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials.
Topics: Acetylcarnitine; Diabetic Neuropathies; Dose-Response Relationship, Drug; Double-Blind Method; Human | 2005 |
Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study.
Topics: Acetylcarnitine; Adult; Aged; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Middle | 2006 |
A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection.
Topics: Acetylcarnitine; Administration, Oral; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infe | 2007 |
L-acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain.
Topics: Acetylcarnitine; Adolescent; Adult; Aged; Double-Blind Method; Humans; Injections, Intramuscular; Mi | 1995 |
Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients.
Topics: Acetylcarnitine; Adult; Female; HIV Seropositivity; Humans; Male; Middle Aged; Nootropic Agents; Pai | 1997 |
10 other studies available for acetylcarnitine and Pain
| Article | Year |
|---|---|
Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain.
Topics: Acetylcarnitine; Amides; Animals; Carrageenan; Cell Count; Cyclooxygenase 2; Disease Models, Animal; | 2021 |
Effect of acetyl-L-carnitine on hypersensitivity in acute recurrent caerulein-induced pancreatitis and microglial activation along the brain's pain circuitry.
Topics: Acetylcarnitine; Acute Disease; Animals; Brain; Ceruletide; Disease Models, Animal; Male; Mice; Mice | 2021 |
L-Acetyl-carnitine in Patients with Carpal Tunnel Syndrome: Effects on Nerve Protection, Hand Function and Pain.
Topics: Acetylcarnitine; Adult; Analgesics; Carpal Tunnel Syndrome; Female; Humans; Male; Median Nerve; Midd | 2017 |
Prophylactic role of acetyl-l-carnitine on knee lesions and associated pain in a rat model of osteoarthritis.
Topics: Acetylcarnitine; Animals; Chondrocytes; Disease Models, Animal; Male; Osteoarthritis, Knee; Pain; Pa | 2014 |
The neuropathy-protective agent acetyl-L-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain.
Topics: Acetylcarnitine; Animals; Disease Models, Animal; Enzyme Activation; Functional Laterality; Hyperalg | 2010 |
Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain.
Topics: Acetylcarnitine; Animals; Chronic Disease; Epigenesis, Genetic; Humans; Pain; Pain Management; Recep | 2010 |
Acetyl-L-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy.
Topics: Acetylcarnitine; Analgesics; Animals; Constriction, Pathologic; Ganglia, Spinal; Male; Nerve Growth | 2010 |
Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy.
Topics: Acetylcarnitine; Activating Transcription Factor 3; Adenosine Triphosphate; Analysis of Variance; An | 2012 |
Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy.
Topics: Acetylcarnitine; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Male; Paclitaxel; | 2006 |
Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells.
Topics: Acetylcarnitine; Animals; Axons; Behavior, Animal; Disease Models, Animal; Drug Interactions; Langer | 2008 |